{"id":745033,"date":"2014-02-10T08:43:00","date_gmt":"2014-02-10T08:43:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-samsung-bioepis-enter-collaboration-agreement-to-develop-and-commercialize-insulin-glargine-candidate-for-diabetes\/"},"modified":"2023-03-22T00:04:59","modified_gmt":"2023-03-22T04:04:59","slug":"merck-and-samsung-bioepis-enter-collaboration-agreement-to-develop-and-commercialize-insulin-glargine-candidate-for-diabetes","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-samsung-bioepis-enter-collaboration-agreement-to-develop-and-commercialize-insulin-glargine-candidate-for-diabetes\/","title":{"rendered":"Merck and Samsung Bioepis Enter Collaboration Agreement to Develop and Commercialize Insulin Glargine Candidate for Diabetes"},"content":{"rendered":"<p>\n      Merck (NYSE:MRK), known as MSD outside the United States and Canada, and<br \/>\n      Samsung Bioepis Co., Ltd., announced today that they have expanded their<br \/>\n      collaboration with an agreement to develop, manufacture and<br \/>\n      commercialize MK-1293, an insulin glargine candidate for the treatment<br \/>\n      of patients with type 1 and type 2 diabetes. Phase III clinical studies<br \/>\n      in type 1 and type 2 diabetes will begin soon.\n    <\/p>\n<p>\n      \u201cWe look forward to collaborating with Samsung Bioepis on this insulin<br \/>\n      glargine candidate, as diabetes is a top priority for the company,\u201d said<br \/>\n      Matt Strasburger, senior vice president, Diabetes, Global Human Health,<br \/>\n      Merck. \u201cMerck is strengthening its leadership in diabetes through our<br \/>\n      own work and in collaboration with others, and this agreement will help<br \/>\n      build our portfolio across the spectrum of the disease.\u201d\n    <\/p>\n<p>\n      \u201cSamsung Bioepis is very pleased to extend the partnership with Merck to<br \/>\n      the field of diabetes,\u201d said Christopher Hansung Ko, Ph.D., CEO of<br \/>\n      Samsung Bioepis. \u201cThis collaboration will bring better access to<br \/>\n      patients with diabetes worldwide.\u201d\n    <\/p>\n<p>\n      Under the terms of the agreement, the companies will collaborate on<br \/>\n      clinical development, regulatory filings and manufacturing. If approved,<br \/>\n      Merck will commercialize this candidate. This collaboration builds on<br \/>\n      the <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.mercknewsroom.com%2Fpress-release%2Fcorporate-news%2Fmerck-and-samsung-bioepis-enter-biosimilars-development-and-commerciali&#038;esheet=50800595&#038;newsitemid=20140210005376&#038;lan=en-US&#038;anchor=agreement&#038;index=1&#038;md5=70e66eed41ab561495efb9d192bd9ca1\" rel=\"nofollow\">agreement<\/a><br \/>\n      made by the two companies in February 2013 to develop and commercialize<br \/>\n      multiple biosimilar candidates.\n    <\/p>\n<p>\n      <b>About Samsung Bioepis<\/b>\n    <\/p>\n<p>\n      Samsung Bioepis, a joint venture between Samsung Biologics and Biogen<br \/>\n      Idec, aims to develop affordable and high-quality biopharmaceutical and<br \/>\n      biosimilar products. For more information, please visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.samsungbioepis.com&#038;esheet=50800595&#038;newsitemid=20140210005376&#038;lan=en-US&#038;anchor=www.samsungbioepis.com&#038;index=2&#038;md5=24e0345842254ca922a6d350192fcb12\" rel=\"nofollow\">www.samsungbioepis.com<\/a>.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today&#8217;s Merck is a global healthcare leader working to help the world be<br \/>\n      well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies, and<br \/>\n      consumer care and animal health products, we work with customers and<br \/>\n      operate in more than 140 countries to deliver innovative health<br \/>\n      solutions. We also demonstrate our commitment to increasing access to<br \/>\n      healthcare through far-reaching policies, programs and partnerships. For<br \/>\n      more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&#038;esheet=50800595&#038;newsitemid=20140210005376&#038;lan=en-US&#038;anchor=vip2-msd.com\/merckcom-migrated&#038;index=3&#038;md5=3d8e7fd224a8ed86589ef34767882863\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=https%3A%2F%2Ftwitter.com%2FMerck&#038;esheet=50800595&#038;newsitemid=20140210005376&#038;lan=en-US&#038;anchor=Twitter&#038;index=4&#038;md5=425154c0aa97f8209eca417d9edbb016\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.facebook.com%2FMerckBeWell&#038;esheet=50800595&#038;newsitemid=20140210005376&#038;lan=en-US&#038;anchor=Facebook&#038;index=5&#038;md5=fd8c655dd04ca3e908ea45e61eef337d\" rel=\"nofollow\">Facebook<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.youtube.com%2FMerck&#038;esheet=50800595&#038;newsitemid=20140210005376&#038;lan=en-US&#038;anchor=YouTube&#038;index=6&#038;md5=cbdd2aa4e88287fbeef41298c52ef09a\" rel=\"nofollow\">YouTube<\/a>.\n    <\/p>\n<p>\n      <b>Merck Forward-Looking Statement<\/b>\n    <\/p>\n<p>\n      This news release includes \u201cforward-looking statements\u201d within the<br \/>\n      meaning of the safe harbor provisions of the United States Private<br \/>\n      Securities Litigation Reform Act of 1995. These statements are based<br \/>\n      upon the current beliefs and expectations of Merck\u2019s management and are<br \/>\n      subject to significant risks and uncertainties. There can be no<br \/>\n      guarantees with respect to pipeline products that the products will<br \/>\n      receive the necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include, but are not limited to, general<br \/>\n      industry conditions and competition; general economic factors, including<br \/>\n      interest rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and healthcare legislation in the<br \/>\n      United States and internationally; global trends toward healthcare cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; Merck\u2019s ability to accurately<br \/>\n      predict future market conditions; manufacturing difficulties or delays;<br \/>\n      financial instability of international economies and sovereign risk;<br \/>\n      dependence on the effectiveness of Merck\u2019s patents and other protections<br \/>\n      for innovative products; and the exposure to litigation, including<br \/>\n      patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      Merck undertakes no obligation to publicly update any forward-looking<br \/>\n      statement, whether as a result of new information, future events or<br \/>\n      otherwise. Additional factors that could cause results to differ<br \/>\n      materially from those described in the forward-looking statements can be<br \/>\n      found in Merck\u2019s 2012 Annual Report on Form 10-K and the company\u2019s other<br \/>\n      filings with the Securities and Exchange Commission (SEC) available at<br \/>\n      the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.sec.gov%2F&#038;esheet=50800595&#038;newsitemid=20140210005376&#038;lan=en-US&#038;anchor=www.sec.gov&#038;index=7&#038;md5=a49010f31297709c64eb053bd20ca799\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p class=\"bwalignc\">\n<p><img decoding=\"async\" alt=\"\" src=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&#038;sty=20140210005376r1&#038;sid=hq1sf1&#038;distro=nx\" \/><span class=\"bwct31415\"\/><\/span><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">Photos\/Multimedia Gallery Available: <\/span><span id=\"mmgallerylink-link\"><a href=\"http:\/\/www.businesswire.com\/multimedia\/home\/20140210005376\/en\/\" rel=\"nofollow\">http:\/\/www.businesswire.com\/multimedia\/home\/20140210005376\/en\/<\/a><\/span><\/p>\n<p>       Merck Media Inquiries<br \/>Kim Hamilton, 908-423-6831<br \/>or<br \/>Caroline        Lappetito, 267-305-7639<br \/>or<br \/>Merck Investor Relations<br \/>Carol        Ferguson, 908-423-4465<br \/>or<br \/>Samsung Media Inquiries<br \/>HongSeok        Ji, +82-32-455-6102<br \/>or<br \/>Samsung Investor Relations<br \/>Sungjoon        Park, +82-32-455-6120     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Samsung Bioepis Co., Ltd., announced today that they have expanded their collaboration with an agreement to develop, manufacture and commercialize MK-1293, an insulin glargine candidate for the treatment of patients with type 1 and type 2 diabetes. Phase III clinical studies in type 1 and type 2 diabetes will begin soon. \u201cWe look forward to collaborating with Samsung Bioepis on this insulin glargine candidate, as diabetes is a top priority for the company,\u201d said Matt Strasburger, senior vice president, Diabetes, Global Human Health, Merck. \u201cMerck is strengthening its leadership in diabetes through our own work and in collaboration with others, and this agreement will help build our portfolio across the spectrum of the disease.\u201d \u201cSamsung Bioepis is very pleased to extend the partnership with Merck to the field of diabetes,\u201d said Christopher Hansung Ko, Ph.D., CEO of Samsung Bioepis. \u201cThis collaboration will bring<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,289],"class_list":["post-745033","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck and Samsung Bioepis Enter Collaboration Agreement to Develop and Commercialize Insulin Glargine Candidate for Diabetes - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-samsung-bioepis-enter-collaboration-agreement-to-develop-and-commercialize-insulin-glargine-candidate-for-diabetes\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck and Samsung Bioepis Enter Collaboration Agreement to Develop and Commercialize Insulin Glargine Candidate for Diabetes - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Samsung Bioepis Co., Ltd., announced today that they have expanded their collaboration with an agreement to develop, manufacture and commercialize MK-1293, an insulin glargine candidate for the treatment of patients with type 1 and type 2 diabetes. Phase III clinical studies in type 1 and type 2 diabetes will begin soon. \u201cWe look forward to collaborating with Samsung Bioepis on this insulin glargine candidate, as diabetes is a top priority for the company,\u201d said Matt Strasburger, senior vice president, Diabetes, Global Human Health, Merck. \u201cMerck is strengthening its leadership in diabetes through our own work and in collaboration with others, and this agreement will help build our portfolio across the spectrum of the disease.\u201d \u201cSamsung Bioepis is very pleased to extend the partnership with Merck to the field of diabetes,\u201d said Christopher Hansung Ko, Ph.D., CEO of Samsung Bioepis. \u201cThis collaboration will bring\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-samsung-bioepis-enter-collaboration-agreement-to-develop-and-commercialize-insulin-glargine-candidate-for-diabetes\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2023-03-22T04:04:59+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20140210005376r1&sid=hq1sf1&distro=nx\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-samsung-bioepis-enter-collaboration-agreement-to-develop-and-commercialize-insulin-glargine-candidate-for-diabetes\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-samsung-bioepis-enter-collaboration-agreement-to-develop-and-commercialize-insulin-glargine-candidate-for-diabetes\\\/\",\"name\":\"Merck and Samsung Bioepis Enter Collaboration Agreement to Develop and Commercialize Insulin Glargine Candidate for Diabetes - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-samsung-bioepis-enter-collaboration-agreement-to-develop-and-commercialize-insulin-glargine-candidate-for-diabetes\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-samsung-bioepis-enter-collaboration-agreement-to-develop-and-commercialize-insulin-glargine-candidate-for-diabetes\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20140210005376r1&sid=hq1sf1&distro=nx\",\"datePublished\":\"2014-02-10T08:43:00+00:00\",\"dateModified\":\"2023-03-22T04:04:59+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-samsung-bioepis-enter-collaboration-agreement-to-develop-and-commercialize-insulin-glargine-candidate-for-diabetes\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-samsung-bioepis-enter-collaboration-agreement-to-develop-and-commercialize-insulin-glargine-candidate-for-diabetes\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-samsung-bioepis-enter-collaboration-agreement-to-develop-and-commercialize-insulin-glargine-candidate-for-diabetes\\\/#primaryimage\",\"url\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20140210005376r1&sid=hq1sf1&distro=nx\",\"contentUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20140210005376r1&sid=hq1sf1&distro=nx\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-samsung-bioepis-enter-collaboration-agreement-to-develop-and-commercialize-insulin-glargine-candidate-for-diabetes\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck and Samsung Bioepis Enter Collaboration Agreement to Develop and Commercialize Insulin Glargine Candidate for Diabetes\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck and Samsung Bioepis Enter Collaboration Agreement to Develop and Commercialize Insulin Glargine Candidate for Diabetes - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-samsung-bioepis-enter-collaboration-agreement-to-develop-and-commercialize-insulin-glargine-candidate-for-diabetes\/","og_locale":"en_US","og_type":"article","og_title":"Merck and Samsung Bioepis Enter Collaboration Agreement to Develop and Commercialize Insulin Glargine Candidate for Diabetes - Merck.com","og_description":"Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Samsung Bioepis Co., Ltd., announced today that they have expanded their collaboration with an agreement to develop, manufacture and commercialize MK-1293, an insulin glargine candidate for the treatment of patients with type 1 and type 2 diabetes. Phase III clinical studies in type 1 and type 2 diabetes will begin soon. \u201cWe look forward to collaborating with Samsung Bioepis on this insulin glargine candidate, as diabetes is a top priority for the company,\u201d said Matt Strasburger, senior vice president, Diabetes, Global Human Health, Merck. \u201cMerck is strengthening its leadership in diabetes through our own work and in collaboration with others, and this agreement will help build our portfolio across the spectrum of the disease.\u201d \u201cSamsung Bioepis is very pleased to extend the partnership with Merck to the field of diabetes,\u201d said Christopher Hansung Ko, Ph.D., CEO of Samsung Bioepis. \u201cThis collaboration will bring","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-samsung-bioepis-enter-collaboration-agreement-to-develop-and-commercialize-insulin-glargine-candidate-for-diabetes\/","og_site_name":"Merck.com","article_modified_time":"2023-03-22T04:04:59+00:00","og_image":[{"url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20140210005376r1&sid=hq1sf1&distro=nx","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-samsung-bioepis-enter-collaboration-agreement-to-develop-and-commercialize-insulin-glargine-candidate-for-diabetes\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-samsung-bioepis-enter-collaboration-agreement-to-develop-and-commercialize-insulin-glargine-candidate-for-diabetes\/","name":"Merck and Samsung Bioepis Enter Collaboration Agreement to Develop and Commercialize Insulin Glargine Candidate for Diabetes - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"primaryImageOfPage":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-samsung-bioepis-enter-collaboration-agreement-to-develop-and-commercialize-insulin-glargine-candidate-for-diabetes\/#primaryimage"},"image":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-samsung-bioepis-enter-collaboration-agreement-to-develop-and-commercialize-insulin-glargine-candidate-for-diabetes\/#primaryimage"},"thumbnailUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20140210005376r1&sid=hq1sf1&distro=nx","datePublished":"2014-02-10T08:43:00+00:00","dateModified":"2023-03-22T04:04:59+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-samsung-bioepis-enter-collaboration-agreement-to-develop-and-commercialize-insulin-glargine-candidate-for-diabetes\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-samsung-bioepis-enter-collaboration-agreement-to-develop-and-commercialize-insulin-glargine-candidate-for-diabetes\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-samsung-bioepis-enter-collaboration-agreement-to-develop-and-commercialize-insulin-glargine-candidate-for-diabetes\/#primaryimage","url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20140210005376r1&sid=hq1sf1&distro=nx","contentUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20140210005376r1&sid=hq1sf1&distro=nx"},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-samsung-bioepis-enter-collaboration-agreement-to-develop-and-commercialize-insulin-glargine-candidate-for-diabetes\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck and Samsung Bioepis Enter Collaboration Agreement to Develop and Commercialize Insulin Glargine Candidate for Diabetes"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"de2b549b-e168-4071-bcca-c6dbec6bc8bb","news_item_aria_label":"","media_files":[{"path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_events\/2014\/02\/1\/logo_merck-logo.jpg","size":"13027","File Upload":""},{"path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_events\/2014\/02\/1\/samsunglogo-5B1-5D.jpg","size":"15561","File Upload":""}],"document_path":"","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745033","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":0,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745033\/revisions"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745033"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745033"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}